trending Market Intelligence /marketintelligence/en/news-insights/trending/P88qIqgdFev5znY-B478Sw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

MetLife offering depositary shares

Infrastructure Issues: Tools to Dig Deep on Potential Risks

Part Two IFRS 9 Blog Series: The Need to Upgrade Analytical Tools

2018 US Property Casualty Insurance Market Report


Fintech Funding Flows To Insurtech In February

MetLife offering depositary shares

MetLife Inc. filed a prospectus related to the sale of 40,000,000 depositary shares, each representing a 0.001 interest in one of its 4.75% noncumulative preferred shares, series F, issued with a liquidation preference of $25,000.

The maximum aggregate offering price is $1 billion.

The company expects net proceeds of approximately $972 million, after the underwriting discount and estimated expenses. Those proceeds will be used for general corporate purposes, possibly including the redemption or repurchase of MetLife's 5.250% fixed- to floating-rate noncumulative preferred shares, series C.

In connection with the sale, MetLife entered into an underwriting agreement and a pricing agreement with Wells Fargo Securities LLC, BofA Securities Inc., Morgan Stanley & Co. LLC, UBS Securities LLC and J.P. Morgan Securities LLC, as representatives of the underwriters.

The joint book runners for the offering are Wells Fargo Securities, BofA Securities, Morgan Stanley, UBS Investment Bank and J.P. Morgan. Barclays, Citigroup, Credit Suisse, Deutsche Bank Securities, Goldman Sachs & Co. LLC and HSBC are acting as co-managers.